REVOLUTION Medicines Inc

24 ago 2026, 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21 ago 2026, 19:46 UTC

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20 ago 2026, 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19 ago 2026, 19:46 UTC

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17 ago 2026, 19:51 UTC

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13 ago 2026, 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12 ago 2026, 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11 ago 2026, 19:36 UTC

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10 ago 2026, 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7 ago 2026, 19:11 UTC

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6 ago 2026, 19:36 UTC

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5 ago 2026, 23:02 UTC

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4 ago 2026, 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3 ago 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 jul 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 jul 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 jul 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 jul 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 jul 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 jul 2026, 18:26 UTC

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 jul 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21 jul 2026, 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20 jul 2026, 17:31 UTC

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.